The Opening Session & 2025 TAT Honorary Award on March 3 set the stage for this year’s Targeted Anticancer Therapies Congress in Paris. Elena Garralda Cabanas, Cristian Massacesi, M.D., and Anastasios Stathis, Prof MD led the session, introducing key discussions on early-phase clinical trials and drug development.
Dr. Philippe Bedard received the TAT Honorary Award, presenting insights on the role of cancer genomics in drug development. Over the following days, experts explored topics including liquid biopsy, cell therapies, new drug targets, and AI in oncology research. Tumor-agnostic approaches in precision medicine and industry perspectives on regulatory and trial challenges were also key areas of discussion.
With over 580 participants and 134 accepted abstracts, this year’s congress brought valuable insights into the evolving landscape of early cancer research.
